Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: A retrospective analysis

Table 3 Prognostic factors for efficacy analysis in hepatocellular carcinoma patients receiving thalidomide

Variables		P value
Overall response rate n (%)
Child-Pugh classification
A	3/30 (10.0)	1.0001
B and C	3/23 (13.0)
Okuda staging
Stage 1	2/27 (7.4	0.3441
Stage 2	3/16 (18.8)
AFP level
> 400 ng/mL	1/31 (3.2)	0.0711
< 400 ng/mL	5/22 (22.7)
A decrease in AFP > 50% after treatment
Yes	5/16 (31.3)	0.0071
No	1/37 (2.7)
Disease control rate n (%)
Child-Pugh Classification
A	6/30 (20.0)	0.2181
B and C	9/23 (39.1)
Okuda staging
Stage 1	6/27 (22.2)	0.7191
Stage 2	5/16 (31.3)
AFP level
> 400 ng/mL	7/31 (22.6)	0.3571
< 400 ng/mL	8/22 (36.4)
A decrease in AFP > 50% after treatment
Yes	7/16 (43.8)	0.0711
No	8/37 (21.6)
Overall survival, mo
Child-Pugh Classification
A	8.8	0.9222
B and C	10.8
Okuda staging
Stage 1	22.2	0.0752
Stage 2	6.9
AFP level
> 400 ng/mL	10.8	0.6792
< 400 ng/mL	6.5
A decrease in AFP > 50% after treatment
Yes	20.7 (95% CI: 1.7-NA)	0.3072
No	7.1 (95% CI: 6.3-24.3)

¹P value was calculated by Fisher’s exact test;

²P value was calculated by Log-rank test. AFP: Alpha fetoprotein; NA: Not assessable.